# Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

> **NCT01103180** · PHASE2 · TERMINATED · sponsor: **University of Chicago** · enrollment: 70 (actual)

## Conditions studied

- Borderline Personality Disorder

## Interventions

- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT01103180
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Funding withdrawn due to inability to accrue
- **Last updated:** 2019-06-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01103180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01103180, "Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01103180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*